Log In Sign up
The largest database of trusted experimental protocols

Igfbp3 elisa

Manufactured by RayBiotech
Visit Supplier

The IGFBP3 ELISA is a quantitative sandwich enzyme-linked immunosorbent assay designed for the measurement of IGFBP3 (Insulin-Like Growth Factor Binding Protein 3) in biological samples. The assay uses two specific antibodies: a capture antibody coated on the microtiter plate and a detection antibody conjugated with a detection system.

Automatically generated - may contain errors

Lab products found in correlation

Pdgf d, by R&D Systems (2 mentions) Igf 1, by Thermo Fisher Scientific (2 mentions) Igfbp3, by ProSpec (2 mentions) Angptl7, by R&D Systems (2 mentions) Epidermal growth factor (egf), by Thermo Fisher Scientific (2 mentions)

Spelling variants of this product

ELISAs (7 citations)

2 protocols using igfbp3 elisa

1

Modulation of Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Identifiers for shRNAs used in this study are: V3LHS-644610 (shFRA1#1), V3LHS-644611 (shFRA1#2), V3LHS-320021 (shIGFBP3#1), V2LHS-111629 (shIGFBP3#2) (Dharmacon, GE Lifesciences). IGFBP3 ELISA (Raybiotech) was performed according to the manufacturer’s instructions with 50ug tumour lysate and conditioned media was diluted 1:5. Recombinant proteins were used at the following conditions: 10ng/ml IGF1 (Invitrogen), 10ng/ml EGF (Invitrogen), 10ng/ml PDGFD (R&D Systems), 2μg/ml IGFBP3 (Prospec) for 15min, or 5ug/ml ANGPTL7 (R&D Systems) for 30min.
Obenauf A.C., Zou Y., Ji A.L., Vanharanta S., Shu W., Shi H., Kong X., Bosenberg M.C., Wiesner T., Rosen N., Lo R.S, & Massagué J. (2015). Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 520(7547), 368-372.
+ Open protocol
+ Expand
2

Modulation of Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Identifiers for shRNAs used in this study are: V3LHS-644610 (shFRA1#1), V3LHS-644611 (shFRA1#2), V3LHS-320021 (shIGFBP3#1), V2LHS-111629 (shIGFBP3#2) (Dharmacon, GE Lifesciences). IGFBP3 ELISA (Raybiotech) was performed according to the manufacturer’s instructions with 50ug tumour lysate and conditioned media was diluted 1:5. Recombinant proteins were used at the following conditions: 10ng/ml IGF1 (Invitrogen), 10ng/ml EGF (Invitrogen), 10ng/ml PDGFD (R&D Systems), 2μg/ml IGFBP3 (Prospec) for 15min, or 5ug/ml ANGPTL7 (R&D Systems) for 30min.
Obenauf A.C., Zou Y., Ji A.L., Vanharanta S., Shu W., Shi H., Kong X., Bosenberg M.C., Wiesner T., Rosen N., Lo R.S, & Massagué J. (2015). Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 520(7547), 368-372.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!